A novel series of benzimidazolo-[1,2,4]triazole-tetrazole derivatives was synthesized and evaluated for anticancer potential through integrated in silico and in vitro approaches. Molecular docking against the 8GVZ anticancer target revealed that compounds 4, 5, 7, 9, and 11 exhibited superior binding affinities, surpassing the reference drug 5-fluorouracil. ADMET predictions confirmed favorable pharmacokinetic and toxicity profiles, supporting their drug-likeness. Subsequent in vitro assays against MCF-7 breast cancer cells demonstrated potent cytotoxicity, with compound 11 showing the lowest IC₅₀ value (0.21 μM). These findings highlight compound 11 and its analogs as promising leads for further anticancer drug development.